Torrent Pharma Q2 results: Net profit soars 30% YoY to ₹591 crore, revenue rises 14%

The drug manufacturer had clocked a profit of ₹453 crore during the September quarter of FY25, it said in a regulatory filing.

Its total revenue from operations advanced 14% annually to ₹3,302 crore during the second quarter of FY26, as compared to ₹2,889 crore in the same quarter of the previous financial year.

On a geographical basis, its revenue from the Indian market witnessed a 12% YoY growth to ₹1,820 crore during the quarter under review, as against ₹1,632 crore in the September quarter of FY25, driven by outperformance in focus therapies.

It clocked ₹337 crore in revenue from the US market in Q2FY26, marking a 26% annual growth from ₹268 crore. Its revenue from the German market rose 5% YoY to ₹303 crore, in contrast to ₹288 crore in the year-ago period.

The Brazilian market contributed ₹318 crore to its revenue, showcasing a 21% annual jump from ₹263 crore. Furthermore, its revenue from other markets was at ₹524 crore, up 20% YoY from ₹438 crore.

Its operational EBITDA (earnings before interest, tax, depreciation, and amortisation) stood at ₹1,083 crore during the reporting quarter, reflecting a 15% YoY increase from ₹939 crore in Q2FY25.

Torrent Pharma share performance

Shares of Torrent Pharma closed 0.78% higher at ₹3,581 apiece on the National Stock Exchange (NSE) on Friday. However, the results were declared after the markets closed.

The stock has gained 0.25% over the last five days and above 1% over the month. It has advanced nearly 9% in the past six months. On a year-to-date basis, it has risen approximately 5%.

While the scrip reached a 52-week high of ₹3,787.90 on July 30, 2025, it touched a year’s low of ₹2,886.45 per equity share on March 3, 2025.

The drugmaker has a total market capitalisation of ₹1.21 lakh crore, as of November 7, 2025, according to data on the NSE.